References
- Catenacci DVT, Schiller GJ. Myelodysplasic syndromes: a comprehensive review. Blood Rev. 2005;19(6):301–319.
- Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361(19):1872–1885.
- Disperati P, Ichim CV, Tkachuk D, et al. Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology. Leuk Res. 2006;30(2):233–239.
- Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536–1542.
- Greenberg PL, Attar E, Bennett JM, National Comprehensive Cancer Network, et al. NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. J Natl Compr Canc Netw. 2011;9(1):30–56.
- Cogle CR, Iannacone MR, Yu D, et al. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment – Clinicalkey. Leuk Res. 2014;38(1):71–75.
- Cogle CR, Craig BM, Rollison DE, et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117(26):7121–7125.
- National Cancer Institute. Surveillance research program, SEER*Stat software version 8.3.5; 2019 [cited 2019 Feb 20]. https://seer.cancer.gov/registries/terms.html.
- Sekeres MA. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010;24(2):287–294.
- Sweeney MR, Applebaum KM, Arem H, et al. Medical conditions and modifiable risk factors for myelodysplastic syndrome: a systematic review. Cancer Epidemiol Biomarkers Prev. 2019;28(9):1502–1517.
- Wang X, Chan AT, Slattery ML, et al. Influence of smoking, body mass index, and other factors on the preventive effect of nonsteroidal anti-inflammatory drugs on colorectal cancer risk. Cancer Res. 2018;78(16):4790–4799.
- Dierssen-Sotos T, Gómez-Acebo I, de Pedro M, et al. Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish multi-case-control (MCC) study. BMC Cancer. 2016;16(1):660.
- Walter RB, Milano F, Brasky TM, et al. Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) Study. J Clin Oncol. 2011;29(17):2424–2431.
- Kasum CM, Blair CK, Folsom AR, et al. Non-steroidal anti-inflammatory drug use and risk of adult leukemia. Cancer Epidemiol Biomarkers Prev. 2003;12(6):534–537.
- Ross JA, Blair CK, Cerhan JR, et al. Nonsteroidal anti-inflammatory drug and acetaminophen use and risk of adult myeloid leukemia. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1741–1750.
- Tan X-L, Reid Lombardo KM, Bamlet WR, et al. Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. Cancer Prev Res. 2011;4(11):1835–1841.
- Poynter JN, Richardson M, Blair CK, et al. Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes. Cancer Epidemiol. 2016;40:134–140.
- Pease DF, Ross JA, Poynter JN, et al. Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients. Cancer Epidemiol. 2015;39(2):222–228.
- Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951.
- Østgård LSG, Nørgaard M, Pedersen L, et al. NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study. Cancer Manag Res. 2018;10:5043–5051.
- Zhang Z, Chen F, Shang L. Advances in antitumor effects of NSAIDs. Cancer Manag Res. 2018;10:4631–4640.
- Sjödahl R. Extent, mode, and dose dependence of anticancer effects. Am J Med. 2001;110(1):S66–S69.
- Bergman K, Müller L, Teigen SW. The genotoxicity and carcinogenicity of paracetamol: a regulatory (re) view. Mutat Res Mol Mech Mutagen. 1996;349(2):263–288.
- Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94(4):252–266.